Skip to main content
Premium Trial:

Request an Annual Quote

NIMH Offering $5M for Genomic Approaches to Bipolar Disorder, Schizophrenia

NEW YORK (GenomeWeb News) —The National Institute of Mental Health will fund seven or eight grants with a total of around $5 million to use genomic approaches to study schizophrenia and bipolar disorder, the National Institutes of Health said last week.
The funding, which will go to both R01 and R01 collaborative awards, is aimed at expanding existing resources for schizophrenia and bipolar disorder research under the NIMH’s Human Genetics Initiative. Researchers will use the funds to apply genomic and related tools to advance the knowledge of the molecular origins of these diseases.
Areas of investigation under these grants may include, but are not limited to, combining data sets generated under this initiative with existing ones to replicate previous findings or detect additional genes underlying these disorders; combining samples from different studies using different methods and studying innovative and cost-sparing ways for phenotypic and genomic analyses; conducting studies that allow for rapid and cost-effective ascertainment, recruitment, and clinical assessment of study subjects for large-scale genetic studies of schizophrenia or bipolar disorder; analyzing genes known to be related to development of mental disorders; and conducting high-density, whole-genome association analyses using existing technology platforms for SNP typing.
There are no specific budget or project term limits for the research, aside from the standard five-year budget limit. Letters of intent are due April 7 and applications are due May 6.
“Applications submitted in response to this initiative should focus on the rapid collection of large cohorts of clinically well-characterized populations of schizophrenia or bipolar subjects and controls (if appropriate) on a topic related to the genomic or genetic analysis of these traits, employing innovative analytical study designs,” the NIH said in its announcement. “The ultimate goal of successful applications will be to identify specific genomic and functional variants that influence susceptibility to schizophrenia and bipolar disorder.”

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.